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Background: Health-related quality of life studies among adults with type 2 diabetes mellitus, using the EQ-5D,
have been short term and have not assessed change over years. This study assessed the change in health status
and health-related quality of life over 5 years among individuals with and without diabetes.
Methods: Respondents to the US Study to Help Improve Early evaluation and management of risk factors Leading
to Diabetes (SHIELD) completed the EuroQol-5D (EQ-5D) at baseline (2004) and 5 years later (2009). Visual analog
scale (VAS) score and health index score were computed at baseline and year 5, and the change over 5 years was
measured for individuals with type 2 diabetes mellitus (T2DM) and those without diabetes, and T2DM adults with
and without diabetic complications. Linear regression models were used to determine change in EQ-5D score,
controlling for age, gender, race, education, household income, and body mass index (BMI).
Results: There was significantly greater decline in the EQ-5D index score in the T2DM group (-0.031 [SD 0.158]),
compared with those without diabetes (-0.016 [0.141], p = 0.001). Compared with respondents without diabetes,
those with T2DM had a larger reduction in EQ-5D index score, after controlling for demographics (p = 0.001). EQ-5D
VAS score declined over 5 years for both groups: -1.42 (18.1) for the T2DM group, and -0.63 (15.8) for the group
without diabetes, but the between-group difference was not significant either before (p = 0.09) or after (p = 0.12),
controlling for demographics. T2DM respondents with diabetic complications had a greater decline in EQ-5D scores
than T2DM respondents without complications (p < 0.05).
Conclusion: Over a 5-year period, health status of respondents with T2DM declined significantly compared with
those with no diabetes, indicating that the burden of the disease has a long-term detrimental impact. This decline
in health status is likely to impact utility scores (fewer quality-adjusted life years) for economic evaluations.
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During the past decade, there has been a dramatic rise
in diabetes [1]. In the United States, there are 23.5 mil-
lion adults 20 years or older with diabetes [2]. World-
wide, an estimated 366 million people had diabetes in
2011, with the number of people with type 2 diabetes
mellitus (T2DM) increasing in every country [3]. Com-
plications from diabetes include blindness, kidney dis-
ease, macrovascular disease, and neuropathy; diabetes is
the seventh leading cause of death in the US [4].* Correspondence: kathyfox@gforcecable.com
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distribution, and reproduction in any mediumIndividuals with T2DM are known to have lower
health-related quality of life (HRQOL) and more depres-
sive symptomatology than those without diabetes [5-8].
Significant reductions in health status among diabetes
patients compared with other chronic disease popula-
tions have been demonstrated using generic HRQOL
instruments [5]. T2DM has been shown to be frequently
associated with adverse psychological effects, particularly
depression [5,6]. Among Michigan patients with T2DM,
the number of diabetes complications was correlated
with lower HRQOL scores [8]. In a population-based
study of adults with and without T2DM, investigators
found EQ-5D index scores and visual analog scores weretral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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those with 3−5 risk factors for T2DM than for those
with 0−2 risk factors [9]. The majority of these HRQOL
studies in diabetes has focused on the current health
state of patients and has not assessed change in health
state over long periods of time, except for clinical trials
that are short term.
HRQOL measures are used in the evaluation of
healthcare interventions, including cost-effectiveness
analyses [10]. For this purpose, quality-adjusted life years
(QALYs) should be calculated using preferences from
the population as a whole. Studies have suggested that
patients’ values for their own health state affect their
decisions concerning treatment and its health outcomes
[11-13]. The EQ-5D is one HRQOL measure that has
been calibrated with preferences from the whole popula-
tion. Assessments of HRQOL using generic instruments
like the EQ-5D allow for comparisons with other
chronic diseases as well as comparisons with healthy
populations to estimate the incremental burden of
diabetes.
The objective of this present study was to assess the
change in health status and HRQOL over a 5-year
period among adults with and without T2DM, using
data from the Study to Help Improve Early evaluation
and management of risk factors Leading to Diabetes
(SHIELD). Also, the change in health status and HRQOL
among T2DM adults with diabetic complications was
assessed to determine whether complications led to add-
itional disease burden impact. Unlike clinical trials, this
study evaluated change in HRQOL over 5 years among
adults being treated in routine clinical practice. Until
now, the EQ-5D has mostly been used in short-term
studies of less than 2 years [14-16]. Evaluating change in
EQ-5D scores over 5 years will elucidate whether health
status and HRQOL would decline over a long period
time, possibly indicating that longer duration with the
burden of T2DM may lead to continued decline in
HRQOL rather than adjusting to the disease and
stabilization of HRQOL.
Methods
This study is a longitudinal analysis of EQ-5D data col-
lected in 2004 and 2009 among SHIELD respondents
with T2DM and those with no diabetes. SHIELD is a 5-
year, survey-based study conducted to better understand
patterns of health status, health behavior, and knowledge
and attitudes of people living with diabetes and those
with varying levels of cardiometabolic risk.
SHIELD survey
SHIELD included an initial screening phase to identify
cases of interest in the general population (e.g., diabetes
mellitus) and a baseline questionnaire to follow upidentified cases and collect data regarding health status,
health knowledge and attitudes, and current behaviors
and treatments. Subsequently, annual follow-up surveys
were administered for 5 years. A detailed description of
the SHIELD methodology has been published previously
[17,18].
In brief, the screening survey was mailed in April 2004
to a stratified random sample of 200,000 US households,
representative of the US population for geographic resi-
dence, household size and income, and age of head of
household [19], identified by the Taylor Nelson Sofres
National Family Opinion (TNS NFO) panel (Greenwich,
CT). All TNS NFO surveys were voluntary, and no spe-
cial incentives were provided. A response rate of 64%
was obtained for the screening survey. The SHIELD
study was approved by the Quorum Review Board.
A comprehensive baseline survey was mailed in
September–October 2004 to a representative sample of
individuals 18 years of age or older (n = 22,001) who were
identified in the screening survey as having self-reported
type 1 diabetes mellitus or T2DM, no diabetes, or being
at risk for diabetes. Each respondent group was balanced
to be representative of that segment of the population
for age, gender, geographic region, household size, and
income for the US population, and then a random sample
from each group was selected and sent the baseline
survey. A response rate of 72% was obtained for the base-
line survey. The 2009 annual follow-up survey (response
rate of 70%) repeated the EQ-5D instrument for com-
parison with the baseline EQ-5D responses.
Study measures
Respondents were classified as having T2DM based on
their self-report of having been told by a doctor, nurse,
or other healthcare professional that they had T2DM.
Respondents who reported a diagnosis of type 1 diabetes
mellitus or unspecified diabetes were excluded from the
analysis. Respondents who did not report a diagnosis of
T2DM, type 1 diabetes, or unspecified diabetes at base-
line were included in the “no diabetes” group.
The EQ-5D was used as a measure of respondents’
HRQOL and utility values. The EQ-5D includes a de-
scriptive profile and a single index value for health status
[20,21]. The visual analog scale (VAS) records the
respondents’ self-rating for their current HRQOL on a
graduated (0−100) scale, with higher scores for higher
HRQOL [22]. The descriptive system is composed of 5
dimensions of health: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. The VAS pro-
vides a direct valuation of the respondent’s current state
of health, whereas the descriptive system can be
converted into an index score representing a von
Neumann-Morgenstern utility value for current health
[20]. The health states from each of the 5 dimensions
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plying scores from the EQ-5D preference weights eli-
cited from general population samples. These weights lie
on a scale on which full health has a value of 1 and dead
a value of 0. For this study, US population weights were
used to convert to an EQ-5D index score [23].
Diabetes complications reported at the annual follow-
up surveys included ever being diagnosed with retinop-
athy, neuropathy, and nephropathy. Respondents were
classified as having retinopathy if they reported a diag-
nosis of eye disease, blindness, or retinopathy. Neur-
opathy was defined as reporting a diagnosis of nerve
problems of the hands or feet involving pain, tingling, or
numbness, foot ulcers, or amputation. Nephropathy was
defined as a reported diagnosis of chronic kidney dis-
ease, dialysis, end-stage kidney disease, kidney trans-
plant, or protein in the urine.
Statistical analysis
EQ-5D VAS score and health index score were computed
at baseline and 5 years later, and the change over 5 years
measured for respondents with and without T2DM. Com-
parisons between respondents with and without reported
T2DM and comparisons between T2DM respondents
with and without diabetic complications were conducted
using chi-square test for categorical variables and t-tests
for continuous variables. Ordinary linear regression model
was used to evaluate change in EQ-5D score by diabetes
status (T2DM vs. no diabetes), controlling for age, gender,
education, household income, and body mass index (BMI)
as reported at baseline. Statistical significance was set
a priori as p < 0.05.
Results
There were 1,741 respondents with T2DM and 4,543
respondents without diabetes who completed the 2004
and 2009 EQ-5D questionnaires and were included in the
analysis. T2DM respondents were significantly older
(mean age: 60.6 vs. 56.1 years), had higher BMI (33.7 vs.
29.8 kg/m2), and a greater percentage had low education
(35.1% vs. 28.5% with high school degree or less) and low
household income (51.9% vs. 41.8% with annual income
< $40,000), compared with respondents without diabetes
(p< 0.001 for each comparison) (Table 1). At baseline
(2004), 66.6% of the T2DM respondents received oral
antidiabetic medications alone, 8.7% received insulin plus
oral antidiabetic agents, 5.5% received insulin alone, and
19.2% received no diabetes medications. In 2009, 51.1%
of the T2DM respondents received oral antidiabetic medi-
cations alone, 12.5% received insulin plus oral antidiabetic
agents, 9.6% received insulin alone, and 26.8% received no
diabetes medications.
Cross-sectionally, mean EQ-5D scores for 2004 and
2009 were significantly lower among T2DM respondentscompared with respondents without diabetes (p < 0.0001
for both index and VAS scores) (Table 2). Longitudinally,
there was a significantly greater decline in EQ-5D index
score in the T2DM group (mean decline −0.031) com-
pared with respondents without diabetes (−0.016) over
the 5-year period (p = 0.001) (Table 2). EQ-5D VAS score
declined over 5 years for both groups, with a change of
−1.4 for T2DM respondents and −0.6 for respondents
without diabetes. The difference between the T2DM and
No diabetes groups in change in EQ-5D VAS scores was
not statistically significant (p = 0.09).
Multivariate regression adjusted for demographic vari-
ables, including age, gender, race, education, income, and
BMI. Compared with respondents without diabetes,
T2DM respondents had a larger reduction in EQ-5D
index score, after controlling for demographics (p= 0.001)
(Table 3). After controlling for demographic variables,
change in EQ-5D VAS score did not differ between
T2DM respondents and respondents without diabetes
(p= 0.12). Age and gender were significantly associated
with change in EQ-5D score for both the index and VAS,
after controlling for the other covariates.
Approximately 9.8% of T2DM respondents reported a
diagnosis of retinopathy, 25.0% reported a diagnosis of
neuropathy, and 3.3% reported a diagnosis of nephropa-
thy. The decline in EQ-5D index score was significantly
greater among T2DM respondents who reported retin-
opathy, compared with T2DM respondents without ret-
inopathy (p = 0.017) (Table 4). Similarly, the decline in
EQ-5D index score was significantly greater among
T2DM respondents who reported prevalent neuropathy,
compared with T2DM respondents without neuropathy
(p < 0.0001). T2DM respondents with reported nephro-
pathy had a decline in EQ-5D index score that was not
significantly different from the decline among T2DM
respondents without nephropathy (p = 0.43). For change
in EQ-5D VAS score, T2DM respondents who reported
retinopathy had a similar decline as T2DM respondents
without retinopathy (p = 0.88). Although T2DM respon-
dents who reported neuropathy had twice the decline in
EQ-5D VAS score as T2DM respondents without
neuropathy, the difference was not statistically signifi-
cant (p = 0.43). Moreover, T2DM respondents who
reported nephropathy had a significantly greater decline
in EQ-5D VAS score compared with T2DM respondents
without nephropathy (p = 0.01).
Discussion
Over a 5-year period in the present study, health status
of respondents with T2DM declined significantly, com-
pared with adults with no diabetes, indicating that the
burden of disease has a long-term detrimental impact on
the quality of life of individuals living with T2DM. The
decline in EQ-5D index score over 5 years among
Table 1 Characteristics of SHIELD respondents with and without type 2 diabetes mellitus who completed the 2004 and
2009 EQ-5D questionnaires, n = 6,284
Characteristics Type 2 diabetes mellitus (n = 1,741) No diabetes (n = 4,543) p-value
Age, years, mean (SD) 60.6 (11.7) 56.1 (15.0) <0.001
Women,% 60.2 62.4 0.25
White,% 85.4 89.5 <0.001
Education, high school degree or less,% 35.1 28.5 <0.001
Household income, <$40,000,% 51.9 41.8 <0.001
Body mass index, kg/m2, mean (SD) 33.7 (8.0) 29.8 (6.9) <0.001
Duration of diabetes, years, mean (SD) 9.0 (7.8) Not applicable
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dents without diabetes (p=0.001), and the decline in VAS
score was 2.2 times greater, albeit not statistically signifi-
cant. The greater decline in health status among T2DM
respondents remained even after adjusting for baseline dif-
ferences between groups. The absence of significantly
greater decline in VAS score may be due to the VAS being
a single question on overall health currently. As a generic
measure of health status, the VAS may be more influenced
by other major health events such as myocardial infarction,
stroke, and depression than the index score. The signifi-
cantly greater decline in EQ-5D index score in the T2DM
group compared with respondents without diabetes is likely
to impact utility scores for economic evaluations. QALYs
are used as indicators of effectiveness or health outcome in
economic evaluations [24]. Cost-effectiveness studies are
required to help clinicians and healthcare decision-makers
in determining the impact of antidiabetic medications on
both patient outcomes and societal costs. Understanding
patient preferences (index score) for health outcomes is im-
portant for economic evaluations of new therapies, as well
as for understanding patient behavior and adherence to dia-
betes therapy regimens. Thus in the present study, adults
with T2DM would have fewer QALYs gained compared
with adults without diabetes.Table 2 Mean scores and mean change in scores for EQ-5D am
diabetes mellitus
EQ-5D Type 2 diabetes mellitus (n = 1,741)
2004 scores, mean (SD)
Index 0.798 (0.174)
Visual analog 69.05 (19.83)
2009 scores, mean (SD)
Index 0.767 (0.186)
Visual analog 67.63 (19.62)
Change from 2004 to 2009, mean (SD)
Index −0.031 (0.158)
Visual analog −1.416 (18.112)The greater decline in EQ-5D index score over 5 years
for T2DM respondents with reported retinopathy and
neuropathy is likely to impact utility scores in economic
evaluations among adults with T2DM. A mailed ques-
tionnaire to individuals with T2DM in Norway found
that the EQ-5D index score was 0.85 for those without
diabetic complications and 0.73 for those with complica-
tions [25]. A clinical trial of intensive blood glucose con-
trol versus standard treatment in China showed that
patients with microvascular complications reported sig-
nificantly lower EQ-5D index scores than those without
complications; however, there was no significant differ-
ence in HRQOL after 5 years in both groups [26]. In the
present study, the decline in EQ-5D scores was greater
among T2DM respondents with diabetic complications.
From these findings, the presence of diabetic complica-
tions should be accounted for in the evaluation of the
economic burden of T2DM.
The baseline EQ-5D scores in the present study were
similar to those in other studies. Grandy and colleagues
[9] reported cross-sectional EQ-5D scores for the T2DM
respondents from SHIELD in 2004 (0.78 for index and
66.8 for VAS), which were similar to those in the present
study of T2DM respondents who completed both the
2004 and 2009 SHIELD surveys (index = 0.80, VAS= 69.0ong SHIELD respondents with and without type 2







Table 3 Multivariate linear regression for change in EQ-5D scores among adults with and without type 2 diabetes
Variables EQ-5D index score EQ-5D visual analog score
Beta coefficient (SE) p-value Beta coefficient (SE) p-value
T2DM vs. No diabetes −0.015 (0.004) 0.001 −0.762 (0.495) 0.12
Age (per 1 year) −0.001 (0.000) <0.0001 −0.053 (0.015) <0.0001
Women vs. men 0.008 (0.004) 0.04 1.078 (0.441) 0.015
Black vs. white 0.004 (0.007) 0.57 −0.556 (0.836) 0.51
Other race vs. white 0.018 (0.013) 0.16 −2.481 (1.467) 0.09
Body mass index (per 1 kg/m2) 0.000 (0.000) 0.08 0.087 (0.030) 0.004
Income (referent: <$22,500)
$22,500 − $39,999 −0.001 (0.006) 0.82 0.497 (0.641) 0.44
$40,000 − $59,999 −0.006 (0.006) 0.30 0.026 (0.676) 0.97
$60,000 − $89,999 0.002 (0.006) 0.70 −0.687 (0.691) 0.32
>$89,999 0.005 (0.006) 0.40 0.357 (0.709) 0.61
Education (referent: high school degree)
Some high school 0.004 (0.010) 0.72 0.208 (1.137) 0.85
Some college 0.000 (0.005) 0.93 0.153 (0.553) 0.78
College graduate 0.002 (0.006) 0.71 0.512 (0.653) 0.43
Graduate courses/ degree −0.001 (0.006) 0.88 0.170 (0.730) 0.82
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assessing HRQOL in diabetes, in particular, clinical trials
evaluating different diabetes treatments or disease man-
agement programs [14,26-30]. A multi-country European
study found significantly lower EQ-5D VAS scores for
T2DM patients who reported hypoglycemic symptoms
compared with patients not reporting symptoms [28]. A
simulation model of diabetes disease progression showed
that healthier patients with T2DM enjoy more life years,
QALYs, and more life years free of complications [31]. Re-
cent studies have demonstrated the construct, conver-
gent and discriminant validity, test-retest reliability, and
responsiveness of the EQ-5D in T2DM [32]. In a re-
view of studies in T2DM that used the EQ-5D, EQ-5D
index scores ranged from 0.20 for severe diabeticTable 4 Mean change in EQ-5D scores over 5 years






Mean (SD) p-value Mean (SD) p-value
Retinopathy
Yes (n = 171) −0.058 (0.162) 0.017 −1.614 (20.66) 0.88
No (n = 1,570) −0.028 (0.158) −1.394 (17.82)
Neuropathy
Yes (n = 436) −0.061 (0.174) <0.0001 −2.005 (21.12) 0.43
No (n = 1,305) −0.020 (0.152) −1.219 (16.99)
Nephropathy
Yes (n = 58) −0.047 (0.164) 0.43 −7.448 (20.61) 0.01
No (n = 1,683) −0.030 (0.158) −1.208 (17.99)peripheral neuropathic pain to 0.88 for the general
population with good HbA1c levels [32]. Pooled mean
EQ-5D index scores were calculated for 6 subgroups:
general population 0.67 (95% CI: 0.59−0.75), no compli-
cations 0.76 (0.68−0.83), microvascular complications
0.73 (0.57−0.89), macrovascular complications 0.73 (0.57
−0.88), diabetic peripheral neuropathic pain 0.45 (0.39
−0.51), and retinopathy 0.57 (0.46−0.69) [32]. Together
with the present study findings of a decline in ED-5D
index score over 5 years, this would potentially indicate
that the T2DM respondents declined in health and pos-
sibly had diabetic complications that would negatively
impact their QALYs.
EQ-5D scores for the respondents without diabetes
were high; index scores were 0.84 in 2004 and 0.82 in
2009. However, these scores were similar to adults in the
US general population where the mean EQ-5D score
was 0.871 for the total population, 0.884 for men and
0.860 for women, and 0.872 for whites and 0.854 for
blacks [33]. Jia and Lubetkin [33] used the 2000-2003
Medical Expenditure Panel Survey data to determine
that the mean EQ-5D score was 0.825 for US adults in
the general population with less than a high school edu-
cation and 0.859 for those with a high school degree;
28.5% of the respondents without diabetes in the present
study had a high school degree or less. Thus, the EQ-5D
scores in the present study are in alignment with the
general US population.
The present study provides evidence of the impact of
T2DM on HRQOL over 5 years in a large sample using
a standardized, validated measure so that norm-based
results are provided. However, the study has some
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plications were self-reported and could not be validated
with laboratory tests or medical record reviews. How-
ever, this bias is similar between the groups compared in
this study. Household panels, like the TNS NFO panel,
tend to under-represent the very wealthy and very poor
segments of the population and do not include military
or institutionalized individuals. Glucose control, such as
HbA1c level, was not collected in the SHIELD surveys,
so its impact on the decline in HRQOL cannot be
assessed in this study. It is possible that the detrimental
impact of T2DM over the 5 years may in part be due to
poor glucose control. The proportion of T2DM respon-
dents receiving no diabetic medications increased over
time from 19.2% to 26.8%. It is possible that some respon-
dents had improved their glycemic control through diet
and exercise thus lowering their need for anti-diabetic
medications; however, SHIELD did not collect data to
address this supposition.
Another factor limiting the interpretation of the data
is that minimally important differences (MIDs) for the
EQ-5D have not been identified for T2DM patients trea-
ted in clinical practice (rather than clinical trial popula-
tions). The MID of 0.07 for the EQ-5D index score has
been suggested, although the MID was not derived
within samples of patients with T2DM [34-36]. Neither
the T2DM respondents nor respondents without dia-
betes met the MID criterion for the change in EQ-5D
index score.
In conclusion, health status of respondents with
T2DM declined significantly over a 5- year period com-
pared with respondents with no diabetes, indicating that
the burden of disease has a long-term detrimental im-
pact on HRQOL for adults living with T2DM. The sig-
nificantly greater decline in EQ-5D index score in the
T2DM group compared with respondents without dia-
betes, as well as the decline among T2DM respondents
with diabetic complications, is likely to impact utility
scores (fewer QALYs) for economic evaluations.
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